title: BML-11, a lipoxin receptor agonist, protected carbon tetrachloride-induced hepatic fibrosis in rats.
abstract: Inflammation plays an important role in the occurrence and development of fibrosis. Lipoxins (LXs) and BML-111 (lipoxin A4 agonist) have been approved for potent anti-inflammatory properties. Previously, we and others had showed LXs and BML-111 could protect acute hepatic injury, inhibit the growth and invasion of hepatic tumor. However, there are few reports dealing with their effects on hepatic fibrosis. To explore whether LXs and the analog could interrupt the process of hepatic fibrosis, the effects of BML-111 on tetrachloride-induced hepatic fibrosis were observed and the possible mechanism were discussed. Sprague-Dawley rats were induced liver fibrosis by carbon tetrachloride (CCl4) for 10 weeks with or without BML-111, and the histopathology and collagen content were employed to quantify hepatic necro-inflammation and fibrosis. Moreover, the expression levels of α-smooth muscle actin (α-SMA), transforming growth factor-β1 (TGF-β1), and platelet-derived growth factor (PDGF) were examined via Western blot or ELISA. Rats treated with BML-111 improved hepatic necro-inflammation and inhibited hepatic fibrosis in association with reduction of α-SMA expression and decreased collagen deposition. Furthermore, BML-111 could downregulate the expressions of TGF-β1 and PDGF significantly. BML-111 played a critical protective role in CCl4-induced hepatic fibrosis through inhibiting the levels of TGF-β1 and PDGF in rats.
authors: Department of Pathophysiology, Medical College of Nanchang University, 461 BaYi Road, Jiangxi Province, Nanchang, 330006, China.
authors: Xiao-Yan
authors: XY
authors: Zhou
authors: Zhong-Jian
authors: ZJ
authors: Yu
authors: Dan
authors: D
authors: Yan
authors: Hong-Mei
authors: HM
authors: Wang
authors: Yong-Hong
authors: YH
authors: Huang
authors: Juan
authors: J
authors: Sha
authors: Fang-Yun
authors: FY
authors: Xu
authors: Zhen-Yu
authors: ZY
authors: Cai
authors: Wei-Ping
authors: WP
authors: Min
mesh_terms: D000199:Actins / Q000096:biosynthesis; D000818:Animals; D002251:Carbon Tetrachloride; D003094:Collagen / Q000096:biosynthesis; D015536:Down-Regulation / Q000187:drug effects; D015870:Gene Expression; D006538:Heptanoic Acids / Q000494:pharmacology*; D007249:Inflammation / Q000188:drug therapy; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008103:Liver Cirrhosis / Q000139:chemically induced / Q000517:prevention & control*; D010982:Platelet-Derived Growth Factor / Q000096:biosynthesis / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D044067:Receptors, Lipoxin / Q000819:agonists*; D053773:Transforming Growth Factor beta1 / Q000096:biosynthesis / Q000097:blood / Q000378:metabolism*
chemical_list: D000199:Actins; D002251:Carbon Tetrachloride; D003094:Collagen; D006538:Heptanoic Acids; D010982:Platelet-Derived Growth Factor; D044067:Receptors, Lipoxin; D053773:Transforming Growth Factor beta1; C530770:5(S),6(R)-7-trihydroxyheptanoic acid, methyl ester; C482540:lipoxin A(4) receptor, rat; C498862:Acta2 protein, rat
references: J Cell Mol Med. 2006 Jan-Mar;10(1):76-99
references: 16563223
references: Br J Pharmacol. 2010 Oct;161(4):911-24
references: 20860668
references: Cancer Lett. 2011 Oct 1;309(1):85-94
references: 21683517
references: Inflamm Res. 2008 Apr;57(4):157-62
references: 18648754
references: Trends Pharmacol Sci. 2001 Aug;22(8):391-5
references: 11478982
references: Toxicology. 2008 Dec 30;254(3):120-9
references: 18662740
references: Prostaglandins Other Lipid Mediat. 2002 Aug;68-69:433-55
references: 12432935
references: Biochemistry. 1995 Nov 7;34(44):14609-15
references: 7578068
references: Prostaglandins Leukot Essent Fatty Acids. 2005 Sep-Oct;73(3-4):163-77
references: 16125378
references: Resuscitation. 2012 Jul;83(7):907-12
references: 22245750
references: Br J Anaesth. 2011 Dec;107(6):948-58
references: 21990306
references: FASEB J. 2011 Sep;25(9):2967-79
references: 21628447
references: J Am Soc Nephrol. 2002 Oct;13(10):2497-507
references: 12239238
references: Mol Cancer Ther. 2010 Aug;9(8):2164-74
references: 20682645
references: Reprod Toxicol. 2012 Dec;34(4):677-85
references: 23063943
references: Gastroenterology. 2008 May;134(6):1655-69
references: 18471545
references: Proc Natl Acad Sci U S A. 2004 Nov 2;101(44):15736-41
references: 15505205
references: Annu Rev Pathol. 2011;6:425-56
references: 21073339
references: Hepatol Res. 2009 Sep;39(9):921-30
references: 19456898
references: Am J Respir Cell Mol Biol. 2013 May;48(5):610-8
references: 23470626
references: Kidney Int Suppl. 1997 Mar;58:S56-61
references: 9067945
references: Nat Rev Gastroenterol Hepatol. 2010 Aug;7(8):425-36
references: 20585339
references: Biochem Biophys Res Commun. 1991 Nov 14;180(3):1416-21
references: 1659416
references: J Clin Invest. 2011 Aug;121(8):3343-56
references: 21747166
references: J Clin Invest. 2005 Feb;115(2):209-18
references: 15690074
references: Hepatol Res. 2007 Nov;37(11):948-56
references: 17610505
references: FASEB J. 2004 May;18(7):816-27
references: 15117886
references: Nat Med. 2006 Mar;12(3):330-4
references: 16415877
references: Clin Chem Lab Med. 1999 Mar;37(3):293-7
references: 10353475
references: Int J Exp Pathol. 2007 Apr;88(2):85-94
references: 17408451
references: J Clin Gastroenterol. 2002 Nov-Dec;35(5 Suppl 2):S79-85
references: 12394210
references: J Clin Invest. 2007 Mar;117(3):539-48
references: 17332881